ForeSENTIA: Pan-Cancer Core
The ForeSENTIA Pan-Cancer Core panel analyses single nucleotide variants, insertions, deletions, copy number alterations, and rearrangements in 80 genes associated with different types of cancers. It can help identify mutations that can be responsible for cancer development and therapy resistance in solid tumours. The clinical significance of the genes tested has been previously emphasised by professional bodies including NCCN and ESMO. Depending on the type of cancer and the genetic alterations identified, different FDA/EMA-approved drugs as well as eligible clinical trials are available.
Microsatellite instability (MSI) immunotherapy biomarker is also tested in this panel. FDA/EMA-approved immunotherapies, such as pembrolizumab, are also available for patients with MSI-high status depending on their type of cancer.
Created by
Our editorial team consists of medical specialists and scientists in the field of human genetics. All content is created and reviewed in accordance with current scientific standards.
Are you a patient?


Certified laboratories

